Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat: Research-Grade Profile, Mechanisms & Applications

Executive Summary: Atrial Natriuretic Peptide (ANP), rat (C49H84N20O15S), is a 28-amino-acid vasodilator peptide hormone produced by atrial myocytes in response to atrial stretch and neurohormonal stimuli [APExBIO]. ANP promotes natriuresis, diuresis, and vasodilation, directly influencing renal sodium excretion and blood pressure homeostasis (Kishimoto 2021). The peptide’s sequence, solubility, and >95% purity are rigorously validated, supporting reproducibility in cardiovascular and renal physiology research [product]. APExBIO provides this peptide with validated stability and storage parameters, ensuring consistent experimental outcomes. The article details molecular mechanisms, evidence-based benchmarks, application boundaries, and best practices for workflow integration.

Biological Rationale

Atrial Natriuretic Peptide (ANP) is endogenously synthesized, stored, and secreted by cardiac atrial myocytes in mammals, including rats [APExBIO]. Its primary physiological roles include regulation of blood pressure, maintenance of sodium and water homeostasis, and modulation of adipose tissue metabolism (Kishimoto 2021). ANP secretion is triggered by atrial distension, increased blood volume, angiotensin II, endothelin, and sympathetic nervous system activation (Kishimoto 2021). The resulting natriuresis and vasodilation reduce preload and afterload, providing a counter-regulatory mechanism to the renin-angiotensin-aldosterone system (RAAS) (Kishimoto 2021). ANP also influences adipose tissue by promoting lipolysis and modulating adiponectin secretion, linking cardiovascular and metabolic regulation (Zhang et al. 2022).

Mechanism of Action of Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat

ANP binds to the natriuretic peptide receptor-A (NPR-A/GC-A), a membrane-bound guanylate cyclase, leading to increased intracellular cyclic guanosine monophosphate (cGMP) production. Elevated cGMP mediates vasorelaxation in vascular smooth muscle and enhances glomerular filtration rate (GFR) in the kidney. ANP promotes natriuresis by inhibiting epithelial sodium channels and suppressing sodium reabsorption in the renal collecting duct. It antagonizes the RAAS, decreasing renin and aldosterone secretion, and blunts sympathetic nervous system outflow. In adipose tissue, ANP stimulates lipolysis and increases adiponectin release. The molecular actions are sequence-specific, with the active rat peptide having the sequence H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH [APExBIO]. The peptide’s effects are dose-dependent and reversible.

Evidence & Benchmarks

• ANP (C49H84N20O15S), rat, induces natriuresis and diuresis in vivo, lowering systemic blood pressure in rodent models (Kishimoto 2021, https://doi.org/10.1016/j.phrs.2020.104994).
• ANP reduces plasma renin activity and aldosterone concentration, confirming RAAS antagonism (Kishimoto 2021, https://doi.org/10.1016/j.phrs.2020.104994).
• ANP enhances adiponectin secretion, which is neuroprotective and anti-inflammatory in rat models (Zhang et al. 2022, https://doi.org/10.21203/rs.3.rs-2117207/v1).
• APExBIO’s ANP (SKU A1009) demonstrates >95.9% purity and high solubility (≥122.5 mg/mL in DMSO), ensuring reproducibility in cell- and tissue-based assays (https://www.apexbt.com/anp-1-11-rat.html).
• Protocols utilizing APExBIO’s ANP show robust results in cardiovascular, renal, and metabolic research workflows (https://big-endothelin-1.com/index.php?g=Wap&m=Article&a=detail&id=80).

Applications, Limits & Misconceptions

ANP (C49H84N20O15S), rat, is widely used in:

• Cardiovascular research: Studying blood pressure regulation, vasodilator response, and heart failure pathophysiology.
• Renal physiology: Investigating natriuresis, diuresis, and renal sodium handling.
• Adipose tissue metabolism: Assessing lipolysis and adiponectin-mediated anti-inflammatory effects.
• Hypertension research: Elucidating compensatory pathways in blood pressure homeostasis.
• Assay development: Validating bioassays for natriuretic peptide signaling.

For detailed protocol guidance and troubleshooting, see this workflow integration guide (offering advanced troubleshooting beyond this article), or this cell-assay optimization resource (which focuses on cell-based viability, whereas here the focus is natriuresis and blood pressure).

Common Pitfalls or Misconceptions

• ANP (C49H84N20O15S), rat, does not substitute for human or mouse ANP in cross-species studies; species sequence specificity is critical.
• Prolonged storage of ANP solutions at >-20°C or in ethanol leads to peptide degradation and loss of activity.
• ANP is not effective in models lacking functional natriuretic peptide receptors (NPR-A/GC-A knockout models).
• Peptide solubility and purity must be validated for each batch; improper dissolution may cause inconsistent results.
• ANP is not a direct inhibitor of the TLR4/MyD88/NF-κB pathway, but may indirectly modulate inflammation by inducing adiponectin.

Workflow Integration & Parameters

APExBIO’s Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat (SKU A1009), is provided at >95.92% purity, batch-validated by HPLC and mass spectrometry. The peptide is soluble at ≥122.5 mg/mL in DMSO, ≥43.5 mg/mL in water, and insoluble in ethanol. For best results, dissolve in DMSO or sterile water, aliquot, and store at -20°C as a solid. Avoid repeated freeze-thaw cycles and use solutions immediately after preparation. Shipping occurs on blue ice to maintain peptide stability. The product is optimized for cardiovascular research, with compatibility for in vitro, ex vivo, and in vivo assays. For guidance on integration into proliferation or cytotoxicity assays, see the contrast with cell assay best practices, which address solubility troubleshooting not covered in detail here.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat, is a rigorously validated research peptide for investigating cardiovascular, renal, and metabolic pathways. Its defined molecular action and robust evidence base support its use in blood pressure homeostasis, natriuresis studies, and adipose tissue metabolism research. APExBIO provides this peptide at high purity and with proven protocol compatibility. As research advances, precise application and adherence to validated workflows will further clarify the therapeutic and mechanistic roles of natriuretic peptides in disease models.